PPA
KROS icon

Parametric Portfolio Associates’s Keros Therapeutics KROS Stock Holding History

Parametric Portfolio Associates’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,981
Closed -$233K – 3725
2021
Q4 		$233K Buy
+3,981
New +$199K ﹤0.01% 3364
2021
Q2 		– Sell
-3,979
Closed -$245K – 3579
2021
Q1 		$245K Buy
+3,979
New +$252K ﹤0.01% 3798

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Parametric Portfolio Associates's KROS Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Keros Therapeutics (KROS) in Q1 2022, closing a stake of 3,981 shares — an estimated $233K sold.

Parametric Portfolio Associates first reported a position in KROS in Q1 2021 and held it in 2 quarters. The position peaked at $245K in Q1 2021. 107 funds tracked by Wall St. Rank hold KROS as of Q1 2022.

  • Parametric Portfolio Associates reported no remaining Keros Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Parametric Portfolio Associates sold 3,981 Keros Therapeutics shares in Q1 2022, an estimated $233K.
  • Parametric Portfolio Associates first reported a position in Keros Therapeutics in Q1 2021 and held it in 2 quarters.
  • Parametric Portfolio Associates's Keros Therapeutics position peaked at $245K in Q1 2021.
  • 107 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.